|
Last month in San Francisco, Life Science Nation's RESI Conference hosted two family-office panels to discuss investors' motivations for funding therapeutic and medical-device companies, the current trends in this space, and the distinctions between family offices' investment strategies. Given the fact that a good portion of family offices fly below the radar, it is easy to understand why there was standing room only during these two panel discussions.
LSN recruited the panelists from our extensive network of family office investors-a network that we have developed over the past three years. As noted by both panels, family offices have been increasingly making direct investments in life science companies, a trend LSN has been following. The reasons for this trend include avoiding poor returns (as happened during the financial crisis), increasing control over the final investment decision, and having a philanthropic and social impact...
 | |
RESI 4 Biotech Family Office Panel
|
 | |
RESI 4 Medtech Family Office Panel
|
| 
Life Science Investor Mandates 
